Last reviewed · How we verify
NCT03371797: ALERT
Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial
trial testing Valsartan, Amlodipine - in Essential Hypertension in 800 participants. Completed in 5 November 2018.
1 October 2018
Quick facts
| Lead sponsor | PharmEvo Pvt Ltd |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 800 |
| Start date | 20 February 2018 |
| Primary completion | 1 October 2018 |
| Estimated completion | 5 November 2018 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Valsartan, Amlodipine -
Conditions studied
- Essential Hypertension — all drugs for Essential Hypertension →
Sponsor
PharmEvo Pvt Ltd — full company profile →
Who can join
Adults 18 to 70, any sex, with Essential Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine the efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) after 8 weeks of therapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Improving computational drug repositioning through multi-source disease similarity networks.
Le DH. · · 2025 · cited 1× · PMID 40841559 · DOI 10.1038/s41598-025-04772-0 -
Amlodipine/Valsartan (Avsar®): Efficacy in Hypertensive Patients - A Real World Observational Study (ALERT).
Khan KM, Iqtadar S, Nasir M, Siddiqui AS, et al · · 2020 · cited 1× · PMID 32566416 · DOI 10.7759/cureus.8174
Verify or expand the search:
- PubMed search for NCT03371797
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Essential Hypertension
Currently open trials in the same condition.
- NCT07282145 — Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers · Phase 1 · recruiting
- NCT06778239 — Childhood-Onset Essential Hypertension Natural History Study · recruiting
- NCT07051811 — To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension · NA · recruiting
- NCT06643819 — Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A · Phase 3 · recruiting
- NCT05880056 — Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian P · Phase 4 · recruiting
Other PharmEvo Pvt Ltd trials
Trials by the same sponsor.
- NCT03112187 — FLIPS: Ferfer Liposomal Iron Performance Study · Phase 4 · completed
- NCT03104998 — Neotililty Trial: Effect of Coenzyme Q10 on Semen Parameters in Men With Idiopathic Infertility · Phase 4 · withdrawn
- NCT03096327 — TEAM (Trial on Efficacy and Quality of Life Among Asthmatic Patient With Montelukast) · Phase 4 · completed
- NCT02981147 — PEACe: Ivy, Thyme and Cisti Extract (Phytus) Efficacy in Acute Cough · Phase 4 · completed
- NCT03673605 — Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin · Phase 4 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03371797 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PharmEvo Pvt Ltd
- Last refreshed: 8 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03371797.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing